SANKYO PHARMA intends to concentrate on the development and the marketing of innovative and highly effective therapeutic products. The traditional products (e.g. MOBILAT(R) and HIRUDOID(R)), which were acquired as part of the take-over of the Luitpoldwerke back in the early 90s, will be sold off to STADA Arzneimittel AG until 2007.

SANKYO PHARMA Munich will focus its corporate strategy on developing and marketing innovative medicines to treat serious lifestyle conditions such as high blood pressure, diabetes and hyperlipidemia. As a truly European company and a subsidiary of DAIICHI-SANKYO, the second largest pharmaceutical company in Japan, SANKYO PHARMA will invest the majority of its profits in the development of innovative products for the European ethical pharmaceutical market in Germany (Munich, Pfaffenhofen).

The divestment of the well-known brands MOBILAT(R) and HIRUDOID(R) is therefore in line with the company's strategy. The successful marketing of these important products will be continued by STADA Arzneimittel AG, Bad Vilbel. The staggered takeover of the European traditional products brands with a particular focus on Germany, Great Britain and Italy will be completed by the beginning of 2007.

The future of SANKYO PHARMA as a leading European corporation with a strong focus on innovative research and development has already started. Apart from its current core business in the hypertension sector with the product lines OLMETEC(R) and OLMETEC PLUS(R) (substance Olmesartan), SANKYO PHARMA also has some other very promising products in clinical development for the treatment of cardiovascular diseases, arteriosclerosis, diabetes and metabolic syndromes, which will be brought to the market over the next few years.

SANKYO PHARMA will continue to concentrate on the treatment of lifestyle diseases in the future.

Source: SANKYO PHARMA GmbH, Munich, Germany

Bookmark/Search this post with:

| | | | | | | | | | | | | | | | | |